FOGHORN THERAPEUTICS INC (FHTX) Stock News
NASDAQ:FHTX - Nasdaq - US3441741077 - Common Stock - Currency: USD
FHTX Latest News, Press Relases and Analysis
Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences
CAMBRIDGE, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new...
Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates
Foghorn Therapeutics (FHTX) delivered earnings and revenue surprises of 0% and 10.04%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: ATRA
Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update
FHD-909 (LY4050784) advancing in Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary...
Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update
Graco Inc. (GGG): Among Benjamin Graham Stocks for Defensive Investors
We recently published a list of 10 Benjamin Graham Stocks for Defensive Investors. In this article, we are going to take a look at where Graco Inc. (NYSE:GGG) stands against other Benjamin Graham stocks for defensive investors. Markets in early 2025 are a bit like a moody spring—75 degrees one day, stormy the next. After […]
Inovio Pharmaceuticals (INO) Reports Q1 Loss, Tops Revenue Estimates
Inovio (INO) delivered earnings and revenue surprises of 31.08% and 30%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: INO
Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates
Sutro Biopharma (STRO) delivered earnings and revenue surprises of -44.44% and 25.83%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: STRO
Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference
Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors
CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new...
Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors
Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update
- FHD-909 (LY4050784) advancing in Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target...
Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting
Company to share new preclinical combination data for FHD-909 (LY4050784), a potential first-in-class selective SMARCA2 inhibitor, with non-small cell lung...
Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting
Why PVH Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting
- FHD-909 (LY4050784) advancing in an ongoing Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary...
Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting
Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook
First-in-class oral selective SMARCA2 (BRM) inhibitor FHD-909 (LY4050784) continues enrollment in Phase 1 trial for SMARCA4 (BRG1) mutated cancers, with...
Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new...
Foghorn Therapeutics Highlights Program Progress and Strategic Objectives for 2025
Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities
Objective clinical responses by standard response criteria observed in Phase 1 dose escalation trial for FHD-286 in combination with decitabine in patients...